A Phase 3 interventional study of 9vHPV Vaccine and mRNA-1273 Vaccine in Papillomavirus Infections and Coronavirus Disease (COVID-19), sponsored by Merck Sharp & Dohme LLC. Completed at 38 sites in United States. Open to participants aged 9 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 25th largest by enrollment, is one of 5 that started in 2022, is one of 16 in phase 3, and was the 20th registered.
580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China
Ages 10–45 · Women only · Healthy volunteers
Indiana University · Sites in Kenya
Ages 9–49 · Women only · Healthy volunteers
Western Institute for Veterans Research · Sites in United States
Ages 18+
Talia Sainz Costa · Sites in Spain
Ages 9–18 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 9 Years to 11 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 17 · Phase 4 10
First in 2009; this study’s year is marked. 5 started in 2022.
This study's enrollment of 165 is below the median of 229 across 404 interventional studies indexed under Papillomavirus Infections.
Median enrollment 700 across the 31 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
38 studies in Papillomavirus Infections by Merck & Co., Inc: 1 open now, 7 under way, 6 of them phase 3. Of 30 finished, 26 (87%) have results posted.
Among the 38 studies in Papillomavirus Infections by Merck & Co., Inc, this one is the 27th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2022, is one of 26 in phase 3, and was the 35th registered.
Merck & Co., Inc’s Papillomavirus Infections studies by the year they started, since 2000.
3 of the studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04199689Phase 3Merck Sharp & Dohme LLCEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | 2027-01-15 |
| NCT04206813Boston Medical CenterAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | 2026-12 |
| NCT07303751Institut d'Investigació Biomèdica de BellvitgeStudy Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV | 2027-02-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, from their registry updates:
Among Merck & Co., Inc’s 38 in Papillomavirus Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Dose 1 of 9-valent human papillomavirus \[Types 6, 11, 16, 18, 31, 33, 45, 52, 58\] (9vHPV) vaccine administered into the left arm as an intramuscular (IM) injection, AND Dose 1 of the messenger ribonucleic acid (mRNA)-1273 vaccine administered into the right arm as an IM injection on Day 1; participants will then receive Dose 2 of the mRNA-1273 vaccine administered into the right arm as an IM injection at Month 1 and Dose 2 of the 9vHPV vaccine administered into the left arm as an IM injection at Month 6.
Biological: 9vHPV Vaccine · Biological: mRNA-1273 Vaccine
Participants will receive Dose 1 of the mRNA-1273 vaccine administered into the right arm as an IM injection on Day 1 and Dose 2 of the mRNA-1273 vaccine administered into the right arm as an IM injection at Month 1. Participants will then receive Dose 1 of the 9vHPV vaccine administered into the left arm as an IM injection at Month 2 and Dose 2 of the 9vHPV vaccine administered into the left arm as an IM injection at Month 8.
Biological: 9vHPV Vaccine · Biological: mRNA-1273 Vaccine
9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular (IM) injection
Also known as: V503, GARDASIL®9, SILGARD®9
mRNA-1273 50 mcg dose administered as a 0.25-mL IM injection
Also known as: SARS-CoV-2 Vaccine, Moderna COVID-19 Vaccine
Geometric Mean Titers of Anti-Human Papillomavirus Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (9vHPV)
Antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) are reported for both arms for all randomized participants included in the per-protocol immunogenicity (PPI) population. The PPI population is HPV-type specific.
Time frame: Up approximately 4 weeks post vaccination with 9vHPV Dose 2
Geometric Mean Concentrations of SARS-CoV-2 Spike Protein-Specific Binding Antibodies
The geometric mean concentration (GMC) of serum-derived antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein was determined using an electrochemiluminescence (ECL) assay. GMCs are reported for both arms for all randomized participants included in the mRNA-1273 per-protocol (mRNA-1273-PP) population.
Time frame: Up approximately 4 weeks post vaccination with mRNA-1273 Dose 2
Percentage of Participants With ≥1 Solicited Injection-site Adverse Event (AE)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited AEs are predefined local AEs (at the injection site) for which the participant was specifically questioned, and noted by the participant in their vaccine report card (VRC). Per protocol, the percentage of participants with ≥1 solicited injection site AE has been reported separately based on injection site for participants in the Concomitant Group (Day 1 mRNA-1273 Dose 1 right arm; Day 1 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Group (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting for Concomitant Group Day 1 Dose 1 separated by injection site is specific to this outcome only and does not apply to other safety outcomes.
Time frame: Up to approximately Day 7 post vaccination with any study vaccine
Percentage of Participants With ≥1 Solicited Systemic AE
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited AEs are predefined systemic events for which the participant is specifically questioned, and which are noted by the participant in their VRC. Per protocol the percentage of participants who experienced ≥1 solicited systemic (affecting the whole body) AE are reported here for participants in the Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.
Time frame: Up to approximately Day 7 post vaccination with any study vaccine
Percentage of Participants With ≥1 Serious Adverse Event (SAE)
A serious adverse event (SAE) was defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention. Per protocol the percentage of participants who experienced ≥1 SAE are reported here for participants in the Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.
Time frame: Up to approximately Day 28 post vaccination with any study vaccine
Percentage of Participants With ≥1 Vaccine-Related SAE
A SAE was defined as one that results in death, is life threatening, or requires hospitalization/prolongation of existing hospitalization, results in persistent/significant disability/incapacity, is a congenital anomaly/birth defect, or other important medical event that may require medical intervention. An SAE judged by the investigator to be related to the study vaccine is a vaccine-related SAE. Per protocol the percentage of participants who experienced ≥1 vaccine-related SAE are reported here for participants in Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.
Time frame: Up to approximately 9 Months
Percentage of Participants Who Seroconvert to Each of the 9vHPV Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 Following Administration of a 2-Dose Regimen of 9vHPV Vaccine
Serum-derived antibodies to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured with a competitive luminex immunoassay (cLIA). Seroconversion is defined as changing from cLIA anti-HPV seronegative serum antibodies for 9vHPV types at pre-vaccination to cLIA anti-HPV seropositive at 4 weeks post vaccination with 9vHPV Dose 2. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL) for HPV types were as follows: HPV Type 6: ≥34, HPV Type 11: ≥25; HPV Type 16: ≥32, HPV Type 18: ≥26, HPV Type 31: ≥15, HPV Type 33: ≥10, HPV Type 45: ≥10, HPV Type 52: ≥14, and HPV Type 58: ≥10. Percentage of participants who seroconverted are reported for both arms for all randomized participants included in the PPI population. The PPI population is HPV-type specific.
Time frame: Up to approximately 4 weeks post vaccination with 9vHPV Dose 2
Percentage of Participants Who Experience Seroresponse Following Administration of a 2-Dose Regimen of mRNA-1273 Vaccine
Serum-derived antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein was determined using an electrochemiluminescence (ECL) assay. Seroresponse is defined as a ≥4-fold rise in SARS-CoV-2 spike protein-specific binding antibody concentration from baseline to 4 weeks post vaccination with mRNA-1273 Dose 2. Percentage of participants who experience seroresponse are reported for both arms for all randomized participants included in the mRNA-1273-PP population.
Time frame: Up to approximately 4 weeks post vaccination with mRNA-1273 Dose 2
| Milestone | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Started | 82 | 83 |
| Vaccinated: mrna-1273 dose 1 | 81 | 81 |
| Vaccinated: 9vhpv dose 1 | 81 | 72 |
| Vaccinated: mrna-1273 dose 2 | 78 | 78 |
| Vaccinated: 9vhpv dose 2 | 67 | 66 |
| Concomitant group dose 1 day 1: 9vhpv | 81 | 0 |
| Concomitant group dose 1 day 1: mrna-1273 | 81 | 0 |
| Concomitant group dose 2 month 1: mrna-1273 | 78 | 0 |
| Concomitant group dose 2 month 6: 9vhpv | 67 | 0 |
| Non-concomitant group dose 1 day 1: mrna-1273 | 0 | 81 |
| Non-concomitant group dose 2 month 1: mrna-1273 | 0 | 78 |
| Non-concomitant group dose 1 month 2: 9vhpv | 0 | 72 |
| Non-concomitant group dose 2 month 8: 9vhpv | 0 | 66 |
| Completed | 66 | 64 |
| Not completed | 16 | 19 |
| Withdrew: Randomized by mistake without study treatment | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 10 | 10 |
| Withdrew: Lost to follow-up | 6 | 8 |
Antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured using a competitive Luminex immunoassay (cLIA). Per protocol, antibody titers were expressed as milli Merck units/milliliter (mMU/mL). Geometric Mean Titers (GMTs) are reported for both arms for all randomized participants included in the per-protocol immunogenicity (PPI) population. The PPI population is HPV-type specific.
| mMU/mL | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Anti-HPV 6 | 2198.5 (1806.9 to 2674.8) | 1806.8 (1481.8 to 2202.9) |
| Anti-HPV 11 | 1517.6 (1247.5 to 1846.2) | 1138.2 (941.4 to 1376.2) |
| Anti-HPV 16 | 9595.8 (7822.5 to 11771.0) | 7042.3 (5728.2 to 8657.7) |
| Anti-HPV 18 | 2139.2 (1721.3 to 2658.6) | 1713.2 (1372.1 to 2139.1) |
| Anti-HPV 31 | 1695.6 (1383.9 to 2077.3) | 1404.7 (1149.0 to 1717.2) |
| Anti-HPV 33 | 1172.3 (950.8 to 1445.5) | 889.9 (720.2 to 1099.6) |
| Anti-HPV 45 | 518.0 (413.0 to 649.6) | 370.8 (293.6 to 468.4) |
| Anti-HPV 52 | 733.6 (614.4 to 875.9) | 504.7 (421.9 to 603.7) |
| Anti-HPV 58 | 1095.2 (900.5 to 1332.1) | 912.6 (750.3 to 1110.0) |
The geometric mean concentration (GMC) of serum-derived antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein was determined using an electrochemiluminescence (ECL) assay. GMCs are reported for both arms for all randomized participants included in the mRNA-1273 per-protocol (mRNA-1273-PP) population.
| μg/mL | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Geometric Mean Concentrations of SARS-CoV-2 Spike Protein-Specific Binding Antibodies | 763084.3 (673224.4 to 864938.4) | 650527.9 (576365.9 to 734232.5) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited AEs are predefined local AEs (at the injection site) for which the participant was specifically questioned, and noted by the participant in their vaccine report card (VRC). Per protocol, the percentage of participants with ≥1 solicited injection site AE has been reported separately based on injection site for participants in the Concomitant Group (Day 1 mRNA-1273 Dose 1 right arm; Day 1 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Group (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting for Concomitant Group Day 1 Dose 1 separated by injection site is specific to this outcome only and does not apply to other safety outcomes.
| Percentage of Participants | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Concomitant Group: Day 1 -mRNA-1273 Dose 1 (right arm) | 49.4 | — |
| Concomitant Group: Day 1 - 9vHPV Dose 1 (left arm) | 39.5 | — |
| Concomitant Group: Month 1 - mRNA-1273 Dose 2 (right arm) | 35.9 | — |
| Concomitant Group: Month 6 - 9vHPV Dose 2 (left arm) | 26.9 | — |
| Non-concomitant Group: Day 1 - mRNA-1273 Dose 1 (right arm) | — | 55.6 |
| Non-concomitant Group: Month 1 -mRNA-1273 Dose 2 (right arm) | — | 44.9 |
| Non-Concomitant Group: Month 2 - 9vHPV Dose 1 (left arm) | — | 29.2 |
| Non-concomitant Group: Month 8 - 9vHPV Dose 2 (left arm) | — | 43.9 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited AEs are predefined systemic events for which the participant is specifically questioned, and which are noted by the participant in their VRC. Per protocol the percentage of participants who experienced ≥1 solicited systemic (affecting the whole body) AE are reported here for participants in the Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.
| Percentage of Participants | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Concomitant Group: Day 1 - 9vHPV Dose 1 + mRNA-1273 Dose 1 | 33.3 | — |
| Concomitant Group: Month 1 - mRNA-1273 Dose 2 | 33.3 | — |
| Concomitant Group: Month 6 - 9vHPV Dose 2 | 17.9 | — |
| Non-concomitant Group: Day 1 - mRNA-1273 Dose 1 | — | 37.0 |
| Non-concomitant Group: Month 1 - mRNA-1273 Dose 2 | — | 33.3 |
| Non-concomitant Group: Month 2 - 9vHPV Dose 1 | — | 16.7 |
| Non-concomitant Group: Month 8 - 9vHPV Dose 2 | — | 10.6 |
A serious adverse event (SAE) was defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention. Per protocol the percentage of participants who experienced ≥1 SAE are reported here for participants in the Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.
| Percentage of Participants | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Concomitant Group: Day 1 - 9vHPV Dose 1 + mRNA-1273 Dose 1 | 0.0 | — |
| Concomitant Group: Month 1 - mRNA-1273 Dose 2 | 0.0 | — |
| Concomitant Group: Month 6 - 9vHPV Dose 2 | 0.0 | — |
| Non-concomitant Group: Day 1 - mRNA-1273 Dose 1 | — | 0.0 |
| Non-concomitant Group: Month 1 - mRNA-1273 Dose 2 | — | 0.0 |
| Non-concomitant Group: Month 2 - 9vHPV Dose 1 | — | 0.0 |
| Non-concomitant Group: Month 8 - 9vHPV Dose 2 | — | 0.0 |
A SAE was defined as one that results in death, is life threatening, or requires hospitalization/prolongation of existing hospitalization, results in persistent/significant disability/incapacity, is a congenital anomaly/birth defect, or other important medical event that may require medical intervention. An SAE judged by the investigator to be related to the study vaccine is a vaccine-related SAE. Per protocol the percentage of participants who experienced ≥1 vaccine-related SAE are reported here for participants in Concomitant (Day 1 mRNA-1273 Dose 1 right arm + 9vHPV Dose 1 left arm; Month 1 mRNA-1273 Dose 2 right arm; Month 6 9vHPV Dose 2 left arm) and Non-Concomitant Groups (Day 1 mRNA-1273 Dose 1 right arm; Month 1 mRNA-1273 Dose 2 right arm; Month 2 9vHPV Dose 1 left arm; Month 8 9vHPV Dose 2 left arm). Per protocol, reporting is based on time of injection; as 9vHPV Dose 1 AND mRNA-1273 Dose 1 were both given on Day 1 of the Concomitant Group they have been combined below.
| Percentage of Participants | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Concomitant Group: Day 1 - 9vHPV Dose 1 + mRNA-1273 Dose 1 | 0.0 | — |
| Concomitant Group: Month 1 - mRNA-1273 Dose 2 | 0.0 | — |
| Concomitant Group: Month 6 - 9vHPV Dose 2 | 0.0 | — |
| Non-concomitant Group: Day 1 - mRNA-1273 Dose 1 | — | 0.0 |
| Non-concomitant Group: Month 1 - mRNA-1273 Dose 2 | — | 0.0 |
| Non-concomitant Group: Month 2 - 9vHPV Dose 1 | — | 0.0 |
| Non-concomitant Group: Month 8 - 9vHPV Dose 2 | — | 0.0 |
Serum-derived antibodies to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured with a competitive luminex immunoassay (cLIA). Seroconversion is defined as changing from cLIA anti-HPV seronegative serum antibodies for 9vHPV types at pre-vaccination to cLIA anti-HPV seropositive at 4 weeks post vaccination with 9vHPV Dose 2. A participant with anti-HPV cLIA titer at or above the serostatus cutoff values of the cLIA for a given HPV type is considered seropositive for that HPV type. The serostatus cutoffs (milli Merck units/milliliter (mMU/mL) for HPV types were as follows: HPV Type 6: ≥34, HPV Type 11: ≥25; HPV Type 16: ≥32, HPV Type 18: ≥26, HPV Type 31: ≥15, HPV Type 33: ≥10, HPV Type 45: ≥10, HPV Type 52: ≥14, and HPV Type 58: ≥10. Percentage of participants who seroconverted are reported for both arms for all randomized participants included in the PPI population. The PPI population is HPV-type specific.
| Percentage of Participants | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Anti-HPV 6 cLIA ≥34 mMU/ mL | 100.0 (92.5 to 100.0) | 100.0 (92.3 to 100) |
| Anti-HPV 11 cLIA ≥25 mMU/ mL | 100.0 (92.3 to 100.0) | 100.0 (92.7 to 100.0) |
| Anti-HPV 16 cLIA ≥32 mMU/ mL | 100.0 (92.5 to 100.0) | 100.0 (92.3 to 100.0) |
| Anti-HPV 18 cLIA ≥26 mMU/ mL | 100.0 (92.6 to 100.0) | 100.0 (92.3 to 100.0) |
| Anti-HPV 31 cLIA ≥15 mMU/ mL | 100.0 (92.3 to 100.0) | 100.0 (92.5 to 100.0) |
| Anti-HPV 33 cLIA ≥10 mMU/ mL | 100.0 (92.6 to 100.0) | 100.0 (92.5 to 100.0) |
| Anti-HPV 45 cLIA ≥10 mMU/ mL | 100.0 (92.9 to 100.0) | 100.0 (92.5 to 100.0) |
| Anti-HPV 52 cLIA ≥14 mMU/ mL | 100.0 (92.7 to 100.0) | 100.0 (92.6 to 100.0) |
| Anti-HPV 58 cLIA ≥10 mMU/ mL | 100.0 (92.6 to 100.0) | 100.0 (92.6 to 100.0) |
Serum-derived antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein was determined using an electrochemiluminescence (ECL) assay. Seroresponse is defined as a ≥4-fold rise in SARS-CoV-2 spike protein-specific binding antibody concentration from baseline to 4 weeks post vaccination with mRNA-1273 Dose 2. Percentage of participants who experience seroresponse are reported for both arms for all randomized participants included in the mRNA-1273-PP population.
| Percentage of Participants | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Percentage of Participants Who Experience Seroresponse Following Administration of a 2-Dose Regimen of mRNA-1273 Vaccine | 96.4 (87.7 to 99.6) | 95.0 (86.1 to 99.0) |
Collected over Up to approximately 9 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Concomitant Group | 0/82 (0%) | 0/81 (0%) | 55/81 (67.9%) |
| Non-concomitant Group | 0/83 (0%) | 0/81 (0%) | 59/81 (72.8%) |
| Event | Concomitant Group | Non-concomitant Group |
|---|---|---|
| Injection site painGeneral disorders | 46/81 | 52/81 |
| HeadacheNervous system disorders | 26/81 | 30/81 |
| FatigueGeneral disorders | 23/81 | 23/81 |
| LymphadenopathyBlood and lymphatic system disorders | 6/81 | 20/81 |
| Injection site swellingGeneral disorders | 14/81 | 18/81 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/81 | 16/81 |
| ChillsGeneral disorders | 13/81 | 11/81 |
| Injection site erythemaGeneral disorders | 6/81 | 12/81 |
| PyrexiaGeneral disorders | 11/81 | 10/81 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/81 | 10/81 |
| Age, Continuous(Years) | Concomitant Group | Non-concomitant Group | Total |
|---|---|---|---|
| Mean | 9.9 ± 0.9 | 9.9 ± 0.8 | 9.9 ± 0.8 |
| Sex: Female, Male(Participants) | Concomitant Group | Non-concomitant Group | Total |
|---|---|---|---|
| Female | 43 | 45 | 88 |
| Male | 39 | 38 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Concomitant Group | Non-concomitant Group | Total |
|---|---|---|---|
| Hispanic or Latino | 50 | 46 | 96 |
| Not Hispanic or Latino | 32 | 37 | 69 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Concomitant Group | Non-concomitant Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 28 | 31 | 59 |
| White | 53 | 48 | 101 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Mar 2022 to primary completion in Dec 2023, 20 months.
Results were first posted in Jul 2025, 1 year 7 months after primary completion. A results delay was requested in Nov 2024.
Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's 20 months is below that.
Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Human Papillomavirus Recombinant Vaccine nonavalent · 2019-nCoV Vaccine mRNA-1273